Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625313 | 0.87 | SPR (0.46) | SPRKDM4ENPSR1MAPTMEN1 | |
| SCHEMBL1627764 | 0.85 | SPR (0.58) | SPRKDM4ENPSR1POLBGAA | |
| SCHEMBL1626362 | 0.84 | SPR (0.48) | SPRKDM4ENPSR1POLBGAA | |
| SCHEMBL1627752 | 0.82 | SPR (0.48) | SPRKDM4ENPSR1POLBALOX5 | |
| SCHEMBL1627155 | 0.82 | SPR (0.49) | SPRKDM4ENPSR1GAAPDK2 | |
| SCHEMBL1626423 | 0.82 | ALOX5 (0.39) | SPRKDM4EALOX5PDK2MAPT | |
| SCHEMBL1625662 | 0.81 | SPR (0.53) | SPRKDM4ENPSR1MAPTMEN1 | |
| SCHEMBL12720432 | 0.80 | EGLN1 (0.38) | GAAEBP | |
| SCHEMBL1626606 | 0.80 | SPR (0.52) | SPRKDM4ENPSR1POLBGAA | |
| SCHEMBL1626667 | 0.79 | PTPRC (0.38) | KDM4ENPSR1POLBGAAEBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928139-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7635715-B2 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048572-A1 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | EGLN2, EGLN3, HIF1AN | SPR 754/4885KDM4E 977/4885NPSR1 1689/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | SPR 754/4885KDM4E 977/4885NPSR1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.